To compare in vitro and in vivo effects of increased concentrationsof free fatty acids (FFA) on free thyroxin (FT4) values, we measured FT4 in three pooled sera supplemented with oleate and in serum from 18 euthyroid patients before and after an infusion of fat emulsion (Intralipid). We used five FT4 RIA kits: two two-step methods [Gammacoat, Baxter (GC); Ria-gnost, Behring ( The aim of our study was to compare in vitro and in vivo effects of increased FFA concentration in serum on P1'4 results as determined by five assays: two two-step RIAs, two one-step RIAs with labeled T4 analogs, and one onestep RIA with labeled anti-T4 antibodies as tracer. The effect of FFA was studied in vitro by analyzing three pools of sera after supplementing them with oleic acid, and in vivo in patients fed by intravenous fat emulsion. 
(P1'4) in serum is considered a reliable indicator of thyroid status.3 However, the validity of determinations of P1'4 in serum by various methods remains controversial in different clinical situations (1). In severe nonthyroidal illness and during heparin treatment, an increase in the serum concentration of free (nonesterified) fatty acids (FFA) is known to increase or decrease PF, results, depending on the method of P1'4 assay (2) (3) (4) (5) (6) (7) (8) (9) . In fact, FFA competewith thyroid hormones for binding on serum proteins in vitro (10) (11) (12) (13) and some correlations between total FFA or the FFAlalbumin ratio in serum and P1'4 have been found in vivo (8, 9). Unsaturated FFA, particularly oleic acid, are known to contribute more to inhibition of thyroxin-binding activity in patients with nonthyroidal illness than do saturated FFA (5, 10, 12).
The aim of our study was to compare in vitro and in vivo effects of increased FFA concentration in serum on P1'4 results as determined by five assays: two two-step RIAs, two one-step RIAs with labeled T4 analogs, and one onestep RIA with labeled anti-T4 antibodies as tracer. The effect of FFA was studied in vitro by analyzing three pools of sera after supplementing them with oleic acid, and in vivo in patients fed by intravenous fat emulsion.
MaterIals and Methods
In vitro study. Three pooled sera (P1, P2, P3) from euthyroid subjects were tested by the five kits before and after supplementation with increasing concentrations of oleic acid (sodium salt; Sigma Chemical Co., St. Louis, MO): 0.62,1.25,2.5,5,10, and 20 mmol/L. Each sample was analyzed three times.
In vivo study. Eighteen hospitalized patients without severe systemic illness were included in the study after FT4 assays. The two two-step RIA methods we studied, both of which included an immunoextraction step, were the Other assays. FFA concentrations were determined with a commercially available enzymatic assay (N.E.F.A.; Wako Chemicals, Tokyo, Japan). The albumin concentration in serum was quantified with a kit based on the bromcresol blue method (Wako Chemicals).
Statistical

analysis.
Because the frequency distribution of several of the variables studied was nongaussian, group differences were evaluated statistically by the distributionfree Wilcoxon rank test. Correlation coefficients (r) were calculated by Spearman's method, and data were analyzed by simple linear regression.
Resufts
In vitro study. The results of PP4 determinations on the three serum pools with added oleate are summarized in for the GC and RG kits (Table 2 ). These were, the two kits that also showed the most marked change in Pr4 concentrations after addition of oleic acid.
Discussion
The in vitro effect of oleic acid addition on PP4 measurements by GC and RG kits is in agreement with previous results obtained by equilibrium dialysis (4,11,14) and by a two-step chromatographic method (15) . The large increase of P4 with increasing FFA concentrations is considered a result of the competition between these two ligands for binding to serum proteins:
albumin, thyroxin-binding prealbumin, and thyroxin-binding globulin (4) . The biphasic behavior of the AM kit agrees also with previously published data (15, 16) and results from interactions between the thyroxm analog used in the kit and serum proteins (17) .
The moderate effect observed with the two one-step kits (CR and AA) differs from the behavior of the two-step kits used in this study and from those of two one-step enzyme immunoassays: Enzymun-test P1'4 (Boehringer, Mann-heim, F.R.G.) (16) and Amerlite (Amersham) (15) . The in vitro FFA dependence of these two nomsotopic methods is in fact comparable with that of a two-step RIA. The results of the CR and AA kits more resemble those obtained with the Enzelsa kit (Compagnie Oris Industrie, GyfYYvette, France) (15) , in which, as in the AA kit, labeled antibodies are used as tracer.
In the in vivo study, the FFA concentration did not exceed 5 mmol/L-except in one patient-after Intralipid infusion. Under these particular conditions, the results observed in vivo agree with the effect of oleic acid addition in vitro. Despite the lack of a significant difference between pre-and post-Intralipid Pr4 values measured by the RG kit, the increase after infusion is considerable for some samples, but less so than with the GC kit (Figure 2 ).
Different effects of lipids other than oleic acid or of lipemic
blood samples (sera after Intralipid infusion were much more lactescent than the oleate-supplemented in vitro samples) might explain the difference observed between the results of the two two-step methods.
Compared with the increase of PP4 observed with GC and RG kits, the changes noted with the AA and CR kits are much less important. In the study of Mendel et al. (4), who made the same addition of oleic acid in pooled normal serum, the increase of FT4 measured by equilibrium dialysis (89%) was equivalent to the increases observed with the two-step kits. More recently, Nicolson et al. (18) , using a 6 mmol/L oleic acid supplementation, reported also an increase of dialyzable P1'4 (from 0.017% to 0.024%) in plasma from a normal subject and a much more marked increase in plasma from a patient with severe nonthyroidal illness. In vivo, Csako et al. (8), who studied the correlation between Pr4 measured by equilibrium dialysis or by the GC kit and FFA in patients with nonthyroidal illness reputed to have high concentrations of FFA, also observed a marked effect for the two-step kit and equilibrium dialysis method (slope 12.8 with GC kit; 8.6 with equilibrium dialysis). Thus, as discussed by Ekins (19), the weak effect of FFA on P1'4 results by CR and AA methods does not mean that there is no bias. According to the PP4 values given by the two-step or equilibrium dialysis methods, generally considered as "reference" methods because their analytical validity is more firmly established (20, 21) , such a bias certainly exists. However, reliance on equilibrium dialysis as a reference technique for measuring PP4 has been criticized when fatty acids are present in high concentration in serum (22).
In conclusion: For each kit studied, the effects on PP4 results observed in serum in vitro after an oleate addition and in vivo after an Intralipid infusion agreed grossly. The two new kits studied (CR and AA) showed only a weak dependency on FFA increase. These findings imply that increased FT4 values should be less frequently observed and less misleading with these new kits than with two-step RIAs (2, 8) in patients with nonthyroidal illness or in heparin-treated patients with high FFA concentrations. In these two clinical situations FT4 analyzed by CR or AA kit should better agree with a normal result for thyrotropin and the euthyroidal status of the patient (23).
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